Comparative Pharmacology
Head-to-head clinical analysis: FLOWTUSS versus MUCINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOWTUSS versus MUCINEX.
FLOWTUSS vs MUCINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating its removal.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
600 mg orally twice daily (extended-release); for immediate-release: 200 mg orally three times daily or 400 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (CrCl 30–50 mL/min).
1-2 hours (terminal elimination half-life); clinical context: rapid clearance requires frequent dosing to maintain mucolytic effect.
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
Renal: approximately 50-60% as unchanged drug (guaifenesin) and metabolites; minor biliary/fecal elimination (<10%).
Category C
Category C
Expectorant
Expectorant